Patents by Inventor Alan J. Bitonti

Alan J. Bitonti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
    Publication number: 20230023927
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: June 2, 2022
    Publication date: January 26, 2023
    Inventors: Robert T. PETERS, Adam R. MEZO, Daniel S. RIVERA, Alan J. BITONTI, Susan C. LOW
  • FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20220265780
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: January 28, 2022
    Publication date: August 25, 2022
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert PETERS
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 11401322
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 2, 2022
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 11266720
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: March 8, 2022
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
    Publication number: 20220010000
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: September 21, 2021
    Publication date: January 13, 2022
    Inventors: Robert T. PETERS, Adam R. MEZO, Daniel S. RIVERA, Alan J. BITONTI, Susan C. LOW
  • CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA
    Publication number: 20210348150
    Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Application
    Filed: April 23, 2021
    Publication date: November 11, 2021
    Inventors: Daniel S. RIVERA, Robert T. PETERS, Alan J. BITONTI
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 11168125
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: November 9, 2021
    Assignee: BIOVERATIV THERAPEUTICS INC.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 11084866
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 10, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20210220476
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 4, 2020
    Publication date: July 22, 2021
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert T. PETERS
  • Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 10881742
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: May 29, 2018
    Date of Patent: January 5, 2021
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert T. Peters
  • IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
    Publication number: 20200071385
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: July 22, 2019
    Publication date: March 5, 2020
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 10513551
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: December 24, 2019
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • FACTOR VIII-FC CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20190262429
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII: polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: February 7, 2019
    Publication date: August 29, 2019
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert PETERS
  • CELL LINE EXPRESSING SINGLE CHAIN FACTOR VIII POLYPEPTIDES AND USES THEREOF
    Publication number: 20190010212
    Abstract: The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
    Type: Application
    Filed: June 12, 2018
    Publication date: January 10, 2019
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Susan Low, Jennifer A. Dumont, Alan J. Bitonti
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20180360982
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 20, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Jennifer A. DUMONT, Susan LOW, Alan J. BITONTI, Glenn PIERCE, Alvin LUK, Haiyan JIANG, Byron MCKINNEY, Matt OTTMER, Jurg SOMMER, Karen NUGENT, Lian LI, Robert T. PETERS
  • CLOTTING FACTOR-FC CHIMERIC PROTEINS TO TREAT HEMOPHILIA
    Publication number: 20180237762
    Abstract: The invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Application
    Filed: January 9, 2018
    Publication date: August 23, 2018
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Daniel S. Rivera, Robert T. Peters, Alan J. Bitonti
  • Cell line expressing single chain factor VIII polypeptides and uses thereof
    Patent number: 10023628
    Abstract: The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
    Type: Grant
    Filed: July 5, 2013
    Date of Patent: July 17, 2018
    Assignee: Bioverativ Therapeutics Inc.
    Inventors: Susan Low, Jennifer A. Dumont, Alan J. Bitonti
  • IMMUNOGLOBULIN CHIMERIC MONOMER-DIMER HYBRIDS
    Publication number: 20170266309
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Application
    Filed: March 21, 2017
    Publication date: September 21, 2017
    Applicant: Bioverativ Therapeutics Inc.
    Inventors: Robert T. PETERS, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • Immunoglobulin chimeric monomer-dimer hybrids
    Patent number: 9725496
    Abstract: The invention relates to a chimeric monomer-dimer hybrid protein wherein the protein comprises a first and a second polypeptide chain, the first polypeptide chain comprising at least a portion of an immunoglobulin constant region and a biologically active molecule, and the second polypeptide chain comprising at least a portion of an immunoglobulin constant region without the biologically active molecule of the first chain. The invention also relates to methods of using and methods of making the chimeric monomer-dimer hybrid protein of the invention.
    Type: Grant
    Filed: April 19, 2017
    Date of Patent: August 8, 2017
    Assignee: Bioverative Therapeutics Inc.
    Inventors: Robert T. Peters, Adam R. Mezo, Daniel S. Rivera, Alan J. Bitonti, Susan C. Low
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20160222108
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: December 22, 2015
    Publication date: August 4, 2016
    Applicants: DYAX CORP., BIOGEN HEMOPHILIA INC.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James M. McGivney, Kevin A. McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan